US Pharma MarketingThe post Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial appeared first on Clinical Trials Arena.
Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial
Vasomune Therapeutics has completed enrolment in its AV001-004 Phase IIa trial assessing Pegevongitide in patients hospitalised with pneumonia requiring supplemental oxygen. The trial enrolled patients with presumed or confirmed viral or bacterial pneumonia who needed additional oxygen support. Vasomune Therapeutics will focus on data quality, review, cleaning, site closeout, and database lock preparations. Credit: PanuShot / Shutterstock.com. Vasomune Therapeutics has completed enrolment in its AV001-004 Phase IIa trial assessing Pegevongitide (AV-001) in patients hospitalised with pneumonia requiring supplemental oxygen. The randomised, double-blind, placebo-controlled study will examine the safety, tolerability, and exploratory efficacy of intravenously administered Pegevongitide versus placebo, both alongside…
Vasomune Therapeutics has completed enrolment in its AV001-004 Phase IIa trial assessing Pegevongitide in patients hospitalised with pneumonia requiring supplemental oxygen.
Source: Clinical Trials Arena